Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus
- PMID: 15920462
- DOI: 10.1038/sj.gt.3302555
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus
Abstract
Replication-selective oncolytic adenoviruses hold promise, but novel mechanisms must be identified to maximize intratumoral virus persistence, spread and therapeutic transgene-carrying capacity while maintaining safety. One of the main approaches to engineering cancer-selectivity has been to delete a viral gene that is theoretically expendable in cancer cells. Results with this approach have been mixed, however, as evidenced by controversy over Onyx-015 (E1B-55kD(-)) selectivity. We hypothesized that the functional redundancy between viral gene products might limit selectivity and/or potency with this approach. Antiviral immune inducers of apoptosis (eg TNF-alpha) have not been thoroughly investigated in previous studies. We therefore explored whether deletion of functionally redundant viral genes, E1B-19kD and E3B, both independently antagonize TNF-alpha, could lead to enhanced oncolytic potency while maintaining selectivity. Since tumors have numerous blocks in apoptotic pathways, we hypothesized that deletion of one or both gene regions would result in cancer-selectivity in the presence of TNF-alpha. We have previously shown that the E1B-19kD deletion resulted in enhanced viral spread in vitro and in immunocompetent tumor models in vivo. In contrast, the impact of E3B deletion, especially its in vitro selectivity and potency, was not thoroughly characterized, although it resulted in rapid immune-mediated viral clearance in vivo. Furthermore, previous publications indicated that double-deleted mutants have selectivity but unsatisfactory efficacy. We compared the selectivity and potency of E1B-19kD(-), E3B(-) and E1B-19kD(-)/E3B(-) mutants to wild-type adenovirus. In cancer cells, the E1B-19kD(-) mutant had superior replication, spread and cytolysis (+) or (-) TNF-alpha; deletion of both E1B-19kD and E3B was relatively deleterious. In normal cells without TNF-alpha, similar results were obtained. In contrast, all three mutants were significantly inhibited in the presence of TNF-alpha. In immunocompetent mice, all three mutants were significantly inhibited in normal tissue. In tumors, only the E1B-19kD(-) mutant demonstrated enhanced replication, spread and antitumoral efficacy. Therefore, E1B-19kD deletion and E3B retention should be incorporated in oncolytic adenoviruses for enhanced safety and efficacy. In addition, functional redundant viral genes and their biological mediators/targets need to be carefully examined for the next generation of gene-deleted oncolytic viruses.
Similar articles
-
Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.Cancer Gene Ther. 2009 Sep;16(9):703-12. doi: 10.1038/cgt.2009.12. Epub 2009 Feb 20. Cancer Gene Ther. 2009. PMID: 19229289
-
Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.Clin Cancer Res. 2006 Nov 1;12(21):6523-31. doi: 10.1158/1078-0432.CCR-06-1491. Clin Cancer Res. 2006. PMID: 17085667
-
Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.Cancer Gene Ther. 2002 Sep;9(9):725-36. doi: 10.1038/sj.cgt.7700494. Cancer Gene Ther. 2002. PMID: 12189522
-
Oncolytic Replication of E1b-Deleted Adenoviruses.Viruses. 2015 Nov 6;7(11):5767-79. doi: 10.3390/v7112905. Viruses. 2015. PMID: 26561828 Free PMC article. Review.
-
Oncolytic adenoviruses for the treatment of brain tumors.Curr Opin Mol Ther. 2010 Oct;12(5):530-7. Curr Opin Mol Ther. 2010. PMID: 20886384 Review.
Cited by
-
Up-regulation of Mcl-1 and Bak by coronavirus infection of human, avian and animal cells modulates apoptosis and viral replication.PLoS One. 2012;7(1):e30191. doi: 10.1371/journal.pone.0030191. Epub 2012 Jan 11. PLoS One. 2012. PMID: 22253918 Free PMC article.
-
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.Oncotarget. 2016 Mar 29;7(13):15703-24. doi: 10.18632/oncotarget.7310. Oncotarget. 2016. PMID: 26872382 Free PMC article.
-
A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7.Emerg Microbes Infect. 2021 Dec;10(1):1947-1959. doi: 10.1080/22221751.2021.1981157. Emerg Microbes Infect. 2021. PMID: 34520320 Free PMC article.
-
Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.J Transl Med. 2012 Jan 4;10:3. doi: 10.1186/1479-5876-10-3. J Transl Med. 2012. PMID: 22216938 Free PMC article. Review.
-
Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.Clin Cancer Res. 2010 Jan 15;16(2):541-53. doi: 10.1158/1078-0432.CCR-09-1960. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068104 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources